Wybrane najnowsze publikacje naszych autorów

• Tagawa S. T., Sartor O., Piulats J. M., Saad F., Fizazi K., Reid A., Beltran H., Kramer G., Mahammedi H., Eiber M., Gupta S., Castellano D., Hauke R., Kim H., Kwak C., Pang S. T., Barthélémy P., Dai D., Lee J. L., Nordquist L., Szmulewitz R. Z., Wiechno P., Yovine A., Smith L., Bouillaud E., Sakharova O., Morris M. J.; PSMAddition Investigators.: [177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial. Lancet. 2026 Aug 6:S0140-6736(26)01092-5. DOI: 10.1016/S0140-6736(26)01092-5
• Hauschild A., Hassel J. C., Ziemer M., Rutkowski P., Meier F., Flatz L., Gaudy-Marqueste C., Santinami M., Russano F., von Wasielewski I., Eigentler T., Maio M., Zalaudek I., Haferkamp S., Quaglino P., Welzel J., Weichenthal M., Elia G., Covelli A., Lorizzo K., Parca A., Neri D., Ascierto P. A., Robert C., Schadendorf D., Kaehler K. C.: Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial. Journal of Clinical Oncology. 2026 Aug 11:JCO2600852. DOI: 10.1200/JCO-26-00852
• Turner N. C., Mayer E. L., Park Y. H., Janni W., Ma C., Cristofanilli M., Bianchini G., Kalinsky K., Iwata H., Chia S., Brufsky A. M., Fasching P. A., Nowecki Z., Pascual J., Karadurmus N., Gal-Yam E., Chung W-P., Im S-A., Zambelli A., Dalenc F., Oliveira M., Ishiguro H., Huang C-S., Klinowska T., Fox S., Morrow C., Robert L., Huang-Bartlett C., Bidard F-C.: Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Oncology. 2026;27(8):941-958. DOI: 10.1016/S1470-2045(26)00287-1
• Bazarbachi A., Fekom M., Martinez C., Khvedelidze I., Moukalled N., Peggs K. S., Halahleh K., Bramanti S., Giebel S., Aljurf M., Sakellari I., Benakli M., Bonifazi F., Cerretti R., Devillier R., Kulagin A., Nicholson E., Forcade E., Walewski J., Tanase A., Sureda A.: Haematopoietic cell transplantation for relapsed or refractory classical Hodgkin lymphoma: a retrospective, registry-based cohort study of 19 498 patients from the EBMT Lymphoma Working Group. Lancet Haematology. 2026 Aug;13(8):e519-e532. doi: 10.1016/S2352-3026(26)00169-9. DOI: 10.1016/S2352-3026(26)00169-9
• Bernstein-Molho R., Sella T., Delucchi V., Coussy F., Kim H. J., Linn S., Di Meglio A., Pogoda K., Kwong A., Agostinetto E., Bajpai J., Van Herck Y., Ferrari A., Balmana J., Moore H. C. F., Peccatori F. A., Partridge A. H., Winocur M., Renaud T., Rousset-Jablonski C., Lee J. E., Toss A., Paluch-Shimon S., Wong S. M., Matikas A., Villarreal-Garza C., Vernieri C., Lee M., Guven D. C., Cui W., Ruddy K. J., Dieci M. V., Fruscio R., De Marchis L., Kemp Z., Meireles P. A., Razeti M. G., Diz M. D. P., Hwang S. E., Puglisi F., Clatot F., Yerushalmi R., Cichowska-Cwalinska N., Chirco A., De Angelis C., Blondeaux E., Lambertini M.: Chemotherapy type and survival in young BRCA1/2 carriers with HER2-negative early breast cancer. European Journal of Cancer. 2026;245:116937. DOI: 10.1016/j.ejca.2026.116937